▲March 6-7, Shanghai
Yangtze River Delta New Drug Innovators SummitScan for FreeRegistration
Note:This article does not constitute any investment opinions or recommendations., subject to official/company announcements;This article only introduces drugs related to medical health, not a recommendation of treatment options (if involved), and does not represent the platform's position.Any article reprinted must obtain authorization.
Recently, the wave of layoffs in the biopharmaceutical industry has once again drawn widespread attention, with multiple pharmaceutical companies successively announcing team restructuring this year, even into the fourth quarter. The slowdown in preclinical investment, patent expirations, changes in drug pricing regulations, and specific challenges faced by individual companies have forced...Enterprises comprehensively review their "non-core" resources.Domestic pharmaceutical companiesA pharmaceutical companyIn October 2024, approximately 15% of staff were laid off, primarily from the drug research and development team, including personnel supporting early clinical trials. Reportedly, due to some projects failing to meet critical clinical milestones and a tightening financing environment, the company had to reallocate resources.Junshi BiosciencesIn November, the sales team underwent adjustments, with layoffs amounting to approximately 8%. The layoffs were closely related to price reductions of products caused by centralized procurement policies and the poor market performance of some core products. The affected employees were mainly from marketing positions, while support functions were also impacted to a certain extent.China Region of Multinational Pharmaceutical CompaniesJohnson & Johnson ChinaIt was reported that a large-scale layoff was initiated in November, involving up to 2,000 employees, accounting for approximately 20%. The surgical department was the most affected.The main reason for Johnson & Johnson's layoffs is the decline in performance, affected by centralized procurement. The company's previously most important ultrasonic knife business in China held a 95% market share, but now it has fallen to less than 30%, and is still continuing to decline. Pfizer China：Pfizer's Plan to Cut $1.5 Billion in Costs Worldwide Hits China's Sales and Support Teams FirstFrom October 2024 to the end of the year, some business lines with slowed performance growth were streamlined.Pfizer also sold its PCV13 vaccine and eliminated the entire department. It can be foreseen that multinational pharmaceutical companies will likely focus more on cost control to adapt to changes in China's pharmaceutical environment.Bayer China:Bayer Cut Some Non-Core Business Positions in China During the Global Restructuring in October, Including Market Support and Administrative Departments.MSD ChinaIt has been confirmed that staff reductions in the China region primarily affect the diabetes division, although the exact number of layoffs is unknown. In recent years, due to the significant impact of centralized procurement operations, MSD's diabetes business has shrunk considerably, necessitating substantial cost control.Multinational pharmaceutical companiesJohnson & Johnson:According to the latest notice, Johnson & Johnson will lay off 231 employees at its headquarters in New Jersey, and this layoff will officially begin on December 27, 2024.Bayer:Bayer has initiated multiple rounds of layoffs since the beginning of the year, with a total of 3,200 employees affected!But CEO Anderson revealed that Bayer is still in a strong transition period. In order to achieve the goal of saving $541 million in operating expenses for the company, layoffs will continue until 2025. Nowadays, Bayer is continuously moving towards streamlining its business and departments. In order to reduce internal bureaucracy within the group, Bayer has laid off hundreds of middle and senior managers this year, including several executives with nearly 30 years of service.It is reported that Bayer's target for 2026 is to save $2.16 billion, so large-scale layoffs are expected to continue. Novartis:On November 27, Novartis announced that it would lay off nearly 140 employees from its New Jersey plant. The layoffs will begin in February 2025 and continue until August. This will mainly affect the commercial field sales teams for Xolair, Tafinlar, and Mekinist.Amid layoffs, Novartis has increased its investment in its product pipeline, including a potential $1.1 billion acquisition of gene therapy specialist Kate Therapeutics to deepen its neuromuscular expertise, as well as a radiopharmaceutical deal with Ratio Therapeutics that could be worth up to $745 million.BMS：On November 26, in order to reduce expenditures by approximately $1.5 billion by 2025, Bristol-Myers Squibb announced plans to lay off an additional 195 employees from its Lawrenceville, New Jersey facility. The layoffs will begin on February 13, 2025, and continue until the end of next year.BMS mentioned in its comprehensive strategic plan in April 2024 that it would lay off approximately 2,200 employees by the end of this year.Gilead:On November 18, according to the WARN notice, Gilead Sciences and its subsidiary Kite Pharma are laying off 72 people.Starting from January 17, Gilead's Seattle facility will close. On March 14, 2025, 104 employees at its Foster City, California headquarters will be laid off. Kite Pharma will close its Philadelphia facility in mid-2025. The layoffs are due to corporate adjustments to further align resources with long-term strategic goals.Astellas:On November 6, according to the WARN notice, Astellas Gene Therapies continued the phased closure of its San Francisco biomanufacturing facility, and Astellas will lay off 10 employees on January 1.The closure of the facility is expected to be completed in March 2025, affecting approximately 100 employees.It is currently unclear how many of these employees were laid off.。
Copyright statement: This article is reproduced from PharmaTong Society，Media or individuals who do not wish to be reproduced can contact us, and we will delete it immediately.
